2,855
edits
Psychedelics: Difference between revisions
m
→Psychedelic Comparison
m (→History) |
|||
| Line 67: | Line 67: | ||
!Maximum Safe dose | !Maximum Safe dose | ||
!Duration of Experience | !Duration of Experience | ||
!Duration of Open State | |||
|- | |- | ||
|LSD | |LSD | ||
| Line 75: | Line 76: | ||
|1000-3000 μg | |1000-3000 μg | ||
|6-11 hours | |6-11 hours | ||
|3 weeks | |||
|- | |- | ||
|DMT | |DMT | ||
| Line 83: | Line 85: | ||
|100 mg | |100 mg | ||
|15-30 minutes | |15-30 minutes | ||
| - | |||
|- | |- | ||
|Psilocin | |Psilocin | ||
| Line 91: | Line 94: | ||
|150 mg | |150 mg | ||
|3-6 hours | |3-6 hours | ||
|2 weeks | |||
|- | |- | ||
|Mescaline | |Mescaline | ||
| Line 99: | Line 103: | ||
|1000 mg | |1000 mg | ||
|8-15 hours | |8-15 hours | ||
| - | |||
|- | |||
|MDMA | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
|2 weeks | |||
|- | |||
|Ibogaine | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
|>4 weeks | |||
|- | |||
|Ketamine | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
|2 days | |||
|} | |} | ||
[[File:Psychedelic neuroplasticity period.png|alt=Psychedelic neuroplasticity period|thumb|'''Figure 4'''. Psychedelics differ in how long they induce a social reward learning period]] | |||
''Dosage information frequently changes and is dependent on weight and prior medical condition. Before administering check all information with a suitably qualified professional.'' | ''Dosage information frequently changes and is dependent on weight and prior medical condition. Before administering check all information with a suitably qualified professional.'' | ||
A key effect of psychedelics is their ability to open a period of neuroplasticity where old habits can be erased and new habits formed. This period has been found to differ substantially between the various compounds (see '''Figure 4'''). | |||
=== Medicinal Chemistry === | === Medicinal Chemistry === | ||
| Line 126: | Line 161: | ||
==== Microdosing ==== | ==== Microdosing ==== | ||
[[File:Psychedelics exert their effect experientially effect.png|alt=Psychedelics exert their effect experientially|thumb|'''Figure | [[File:Psychedelics exert their effect experientially effect.png|alt=Psychedelics exert their effect experientially|thumb|'''Figure 5.''' Psychedelics exert their effect experientially]] | ||
The medical definition of ''microdosing'' is a dose given which is ''sub therapeutic'', i.e. it is the dose doctors recognise as having no discernible effect. However, many claim, mainly via online survey studies, that very low doses of LSD, taken at 3–4-day intervals, improve mood and cognitive function<ref>'''Exploring the effect of microdosing psychedelics on creativity in an open-label natural setting.''' Prochazkova, L., Lippelt, D.P., Colzato, L.S. ''et al.'' ''Psychopharmacology'' 235, 3401–3413 (2018). <nowiki>https://doi.org/10.1007/s00213-018-5049-7</nowiki></ref>. | The medical definition of ''microdosing'' is a dose given which is ''sub therapeutic'', i.e. it is the dose doctors recognise as having no discernible effect. However, many claim, mainly via online survey studies, that very low doses of LSD, taken at 3–4-day intervals, improve mood and cognitive function<ref>'''Exploring the effect of microdosing psychedelics on creativity in an open-label natural setting.''' Prochazkova, L., Lippelt, D.P., Colzato, L.S. ''et al.'' ''Psychopharmacology'' 235, 3401–3413 (2018). <nowiki>https://doi.org/10.1007/s00213-018-5049-7</nowiki></ref>. | ||
In controlled studies, which in mental health are the gold standard, (see [[Referencing|critical appraisal]]) the placebo effect is excluded. In all of these studies microdosing has been shown to have no effect<ref>'''Repeated low doses of LSD in healthy adults: A placebo-controlled, dose–response study''' Harriet de Wit,Hanna M. Molla,Anya Bershad,Michael Bremmer,Royce Lee First published: 01 February 2022 <nowiki>https://doi.org/10.1111/adb.13143</nowiki>https://onlinelibrary.wiley.com/doi/abs/10.1111/adb.13143</ref> and even in some have shown negative effects such as neuroticism<ref>'''A Systematic Study of Microdosing'''. Richard J. Stevenson, Macquarie University, Sydney, Australia. 10.1371/journal.pone.0211023</ref>. It has been suggested that this is because the experience of the ''trip'' is more important than the underlying chemical-electrical mechanisms<ref>'''The Subjective Effects of Psychedelics Are Necessary for Their Enduring Therapeutic Effects''': David B. Yaden and Roland R. Griffiths* ACS Pharmacol. Transl. Sci. 2021, 4, 2, 568–572. Publication Date:December 10, 2020. <nowiki>https://doi.org/10.1021/acsptsci.0c00194</nowiki></ref> (see '''Figure | In controlled studies, which in mental health are the gold standard, (see [[Referencing|critical appraisal]]) the placebo effect is excluded. In all of these studies microdosing has been shown to have no effect<ref>'''Repeated low doses of LSD in healthy adults: A placebo-controlled, dose–response study''' Harriet de Wit,Hanna M. Molla,Anya Bershad,Michael Bremmer,Royce Lee First published: 01 February 2022 <nowiki>https://doi.org/10.1111/adb.13143</nowiki>https://onlinelibrary.wiley.com/doi/abs/10.1111/adb.13143</ref> and even in some have shown negative effects such as neuroticism<ref>'''A Systematic Study of Microdosing'''. Richard J. Stevenson, Macquarie University, Sydney, Australia. 10.1371/journal.pone.0211023</ref>. It has been suggested that this is because the experience of the ''trip'' is more important than the underlying chemical-electrical mechanisms<ref>'''The Subjective Effects of Psychedelics Are Necessary for Their Enduring Therapeutic Effects''': David B. Yaden and Roland R. Griffiths* ACS Pharmacol. Transl. Sci. 2021, 4, 2, 568–572. Publication Date:December 10, 2020. <nowiki>https://doi.org/10.1021/acsptsci.0c00194</nowiki></ref> (see '''Figure 5''') . By propagating the myth that microdosing does have an effect may cause people from not accessing the correct dose and getting the actual benefit from the medicine. | ||
== Oneirogens == | == Oneirogens == | ||